Metastasis directed radiotherapy (MDRT)

RADIATION2 trials

Sponsors

Centre hospitalier de l'Université de Montréal (CHUM), Case Comprehensive Cancer Center

Conditions

Malignant Neoplasm of ProstateProstate CancerProstate Cancer MetastaticSecondary Malignant Neoplasm of Prostate

Phase 2

Radiotherapy to Consolidate Systemic Response in Metastatic Prostate Cancer (ANCHOR-Prostate)

RecruitingNCT05457699

Centre hospitalier de l'Université de Montréal (CHUM)Prostate Cancer Metastatic

Start: 2022-12-30End: 2030-07-30Target: 80Updated: 2026-09-08

MDRT in Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA)

RecruitingNCT06150417

Case Comprehensive Cancer CenterMalignant Neoplasm of Prostate, Prostate Cancer, Secondary Malignant Neoplasm of Prostate

Start: 2024-07-01End: 2028-12-01Target: 200Updated: 2026-09-15

Related Papers

Platform for the Evaluation of innovations in Radiation oncology through registry-based conduct of multi-centric pragmatic randomized trials: PERa implementation.

2026-04-24

METANOVA: A phase II trial of metastasis-directed radiotherapy for de novo oligometastatic prostate cancer treated with long-term androgen deprivation therapy in the STAMPEDE trial.

Journal of Clinical Oncology2025-05-28